Localized Prostate Cancer Clinical Trial
Official title:
A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)
The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.
This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to
evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate
cancer.
Subjects enrolled will be diagnosed with localized prostate cancer (clinical stage T1/T2)
having a Gleason score of 6 to 7 (3+4 or 4+3). Subjects will receive up to four (4)
transrectal ultrasound (TRUS)-guided IT treatments with Ad5-SGE-REIC/Dkk-3 into the prostate
approximately 6-weeks apart. Each treatment cycle will be performed using a minimum of three
track injections through the prostrate using a total of 3 mL volume. Approximately 2 mL of
the total volume will be injected into the most dense areas of cancer based on biopsy and MRI
mapping (fusion biopsy) and 1 mL total volume will be injected into the opposite lobe of the
prostate or other areas to ensure complete saturation of the prostate over multiple
injections.
Subjects who, in the opinion of the investigator, are progressing at any time after the
second injection of Ad5-SGE-REIC/Dkk-3 may be discontinued and will be treated according to
standard medical practice.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03996005 -
MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
|
N/A | |
Withdrawn |
NCT02159690 -
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
|
Phase 2 | |
Completed |
NCT00196781 -
Treatment Decision Making in Early-Stage Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT03821246 -
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
|
Phase 2 | |
Active, not recruiting |
NCT03814252 -
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer
|
N/A | |
Completed |
NCT01714219 -
Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy
|
N/A | |
Active, not recruiting |
NCT03315754 -
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
|
Phase 2 | |
Recruiting |
NCT05010343 -
Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06325995 -
Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer
|
N/A | |
Recruiting |
NCT06051942 -
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
|
N/A | |
Completed |
NCT02297386 -
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06117059 -
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
|
N/A | |
Withdrawn |
NCT04225299 -
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT06054867 -
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
|
N/A | |
Active, not recruiting |
NCT02435472 -
Active Surveillance Exercise Clinical Trial
|
N/A | |
Completed |
NCT00717613 -
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
|
N/A | |
Completed |
NCT02662673 -
Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device
|
N/A | |
Recruiting |
NCT05155046 -
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
|
Phase 2 | |
Completed |
NCT01902680 -
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.
|
Phase 2 | |
Recruiting |
NCT00651417 -
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue
|
Phase 2 |